Lipid Nanoparticles for Nucleic Acid Delivery and Reusable Nucleic Acid Synthesis Technology

Category: Cell Therapy and Regenerative Medicine

Exhibitor: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE

Booth No: R529

Characteristic

Lipid nanoparticle (LNP) plays an essential role in the development of BNT’s and Moderna’s COVID-19 vaccines to delivery therapeutically nucleic acids. Correspondingly, clinical success of these vaccines represents a milestone for mRNA delivery and lay the groundwork for future nucleic acid therapeutics with this new technology.

ITRI is dedicated to develop key ingredients and proper compositions with the state-of art microfluidic technology to set up a non-viral drug delivering platform, which can produce LNP with various types of nucleic acids (e.g. mRNA、siRNA、miRNA). The LNP with confirmed quality are having to improve stability and translational efficiency of delivering cargo. As showing by current trends in drug development, this platform can be applied to tackle a broad spectrum of diseases, such as cancer, infectious diseases, chronic diseases, rare diseases, etc. by coupling with different biologically active nucleic acids. Meanwhile, we also create short-chain oligonucleotide APIs synthesis system. This innovative reusable short-chain oligonucleotide APIs synthesis system are designed to expand manufacturing capacity with parallel system to satisfy needs of scales in different stages of drug development (i.e. lab, pilot and industrial manufacturing).